Literature DB >> 10741290

A new standard of care for treatment of ovarian cancer.

M J Piccart1, A Du Bois, M E Gore, J P Neijt, S Pecorelli, E Pujade-Lauraine.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10741290     DOI： 10.1016/s0959-8049(99)00210-5

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  4 in total

1.  Non-pegylated liposomal doxorubicin for patients with recurrent ovarian cancer: A multicentric phase II trial.

Authors:  Janina Brucker; Christine Mayer; Gerhard Gebauer; Peter Mallmann; Antje Kristina Belau; Andreas Schneeweiss; Christof Sohn; Michael Eichbaum
Journal:  Oncol Lett       Date:  2016-06-16       Impact factor: 2.967

Review 2.  Imaging and therapy of ovarian cancer: clinical application of nanoparticles and future perspectives.

Authors:  Giovanni Di Lorenzo; Giuseppe Ricci; Giovanni Maria Severini; Federico Romano; Stefania Biffi
Journal:  Theranostics       Date:  2018-07-30       Impact factor: 11.556

3.  Clinical importance of FANCD2, BRIP1, BRCA1, BRCA2 and FANCF expression in ovarian carcinomas.

Authors:  Joanna Moes-Sosnowska; Iwona K Rzepecka; Joanna Chodzynska; Agnieszka Dansonka-Mieszkowska; Lukasz M Szafron; Aneta Balabas; Renata Lotocka; Piotr Sobiczewski; Jolanta Kupryjanczyk
Journal:  Cancer Biol Ther       Date:  2019-03-01       Impact factor: 4.742

4.  Long Noncoding RNA LINC01125 Enhances Cisplatin Sensitivity of Ovarian Cancer via miR-1972.

Authors:  Jia Guo; Hua Pan
Journal:  Med Sci Monit       Date:  2019-12-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.